Novel 2,4-diarylaminopyrimidine analogues (DAAPalogues) showing potent c-Met/ALK multikinase inhibitory activities

ACS Medicinal Chemistry Letters

Volumn 5, Issue 4, 2014, Pages 304-308

  Liu, Zhiqing ^a   Ai, Jing ^b   Peng, Xia ^b   Song, Zilan ^a   Wu, Kui ^c   Zhang, Jing ^a   Yao, Qizheng ^c   Chen, Yi ^b   Ji, Yinchun ^b   Yang, Yanhong ^b   Geng, Meiyu ^b   Zhang, Ao ^a  

^a INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^c CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

2,4 diarylaminopyrimidine analogues; c Met ALK dual inhibitor; C1 Substituted N 3 benzazepine; structure repurposing

Indexed keywords

2,4 DIAMINOPYRIMIDINE DERIVATIVE; 2,4 DIARYLAMINOPYRIMIDINE DERIVATIVE; ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; CYTOKINE RECEPTOR ANTAGONIST; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; IC 50; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 84898021812     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml400373j     Document Type: Article

References (30)

1. Pulford, K.; Lamant, L.; Morris, S. W.; Butler, L. H.; Wood, K. M.; Stroud, D.; Delsol, G.; Mason, D. Y. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1 Blood 1997, 89, 1394-1404
2. Soda, M.; Takada, S.; Takeuchi, K.; Choi, Y. L.; Enomoto, M.; Ueno, T.; Haruta, H.; Hamada, T.; Yamashita, Y.; Ishikawa, Y.; Sugiyama, Y.; Mano, H. A mouse model for EML4-ALK-positive lung cancer Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 19893-19897
3. Rikova, K.; Guo, A.; Zeng, Q.; Possemato, A.; Yu, J.; Haack, H.; Nardone, J.; Lee, K.; Reeves, C.; Li, Y.; Hu, Y.; Tan, Z.; Stokes, M.; Sullivan, L.; Mitchell, J.; Wetzel, R.; Macneill, J.; Ren, J. M.; Yuan, J.; Bakalarski, C. E.; Villen, J.; Kornhauser, J. M.; Smith, B.; Li, D.; Zhou, X.; Gygi, S. P.; Gu, T. L.; Polakiewicz, R. D.; Rush, J.; Comb, M. J. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer Cell 2007, 131, 1190-1203
4. Horn, L.; Pao, W. EML4-ALK: honing in on a new target in non-small-cell lung cancer J. Clin. Oncol. 2009, 27, 4232-4235
5. Gerber, D. E.; Minna, J. D. ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time Cancer Cell 2010, 18, 548-551
6. Casaluce, F.; Sgambato, A.; Maione, P.; Rossi, A.; Ferrara, C.; Napolitano, A.; Palazzolo, G.; Ciardiello, F.; Gridelli, C. ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC Targeted Oncol. 2013, 8, 55-67
7. Lovly, C. M.; Heuckmann, J. M.; de Stanchina, E.; Chen, H.; Thomas, R. K.; Liang, C.; Pao, W. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors Cancer Res. 2011, 71, 4920-4931
8. Mologni, L. Inhibitors of the anaplastic lymphoma kinase Expert Opin. Invest. Drugs 2012, 21, 985-994
9. Galetta, D.; Rossi, A.; Pisconti, S.; Colucci, G. The emerging role of ALK inhibitors in the treatment of advanced non-small cell lung cancer Expert Opin. Ther. Targets 2012, 16, S45-S54
10. Christensen, J. G.; Zou, H. Y.; Arango, M. E.; Li, Q.; Lee, J. H.; McDonnell, S. R.; Yamazaki, S.; Alton, G. R.; Mroczkowski, B.; Los, G. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma Mol. Cancer Ther. 2007, 6, 3314-3322
11. Zou, H. Y.; Li, Q.; Lee, J. H.; Arango, M. E.; McDonnell, S. R.; Yamazaki, S.; Koudriakova, T. B.; Alton, G.; Cui, J. J.; Kung, P. P.; Nambu, M. D.; Los, G.; Bender, S. L.; Mroczkowski, B.; Christensen, J. G. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms Cancer Res. 2007, 67, 4408-4417
12. Comoglio, P. M.; Giordano, S.; Trusolino, L. Drug development of MET inhibitors: targeting oncogene addiction and expedience Nat. Rev. Drug Discovery 2008, 7, 504-516
13. Sakamoto, H.; Tsukaguchi, T.; Hiroshima, S.; Kodama, T.; Kobayashi, T.; Fukami, T. A.; Oikawa, N.; Tsukuda, T.; Ishii, N.; Aoki, Y. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant Cancer Cell 2011, 19, 679-690
14. Sasaki, T.; Janne, P. A. New strategies for treatment of ALK-rearranged non-small cell lung cancers Clin. Cancer Res. 2011, 17, 7213-7218
15. Wu, K.; Ai, J.; Liu, Q.; Chen, T.; Zhao, A.; Peng, X.; Wang, Y.; Ji, Y.; Yao, Q.; Xu, Y.; Geng, M.; Zhang, A. Multisubstituted quinoxalines and pyrido[2,3-d]pyrimidines: synthesis and SAR study as tyrosine kinase c-Met inhibitors Bioorg. Med. Chem. Lett. 2012, 22, 6368-6372
16. Wang, Y. X.; Ai, J.; Yue, J. F.; Peng, X.; Ji, Y. C.; Zhao, A. L.; Gao, X.; Wang, Y.; Chen, Y.; Liu, G.; Gao, Z. B.; Geng, M. Y.; Zhang, A. Further SAR studies on 3,5-diamino-7-trifluoromethyl quinolines as highly potent tyrosine kinase c-Met inhibitors: efforts to correct hERG inhibition MedChemComm 2012, 3, 1423-1427
17. Zhao, A.; Gao, X.; Wang, Y.; Ai, J.; Wang, Y.; Chen, Y.; Geng, M.; Zhang, A. Discovery of novel c-Met kinase inhibitors bearing a thieno[2,3-d]pyrimidine or furo[2,3-d]pyrimidine scaffold Bioorg. Med. Chem. 2011, 19, 3906-3918
18. Wang, Y.; Ai, J.; Wang, Y.; Chen, Y.; Wang, L.; Liu, G.; Geng, M.; Zhang, A. Synthesis and c-Met kinase inhibition of 3,5-disubstituted and 3,5,7-trisubstituted quinolines: identification of 3-(4-acetylpiperazin-1-yl)-5- (3-nitrobenzylamino)-7- (trifluoromethyl)quinoline as a novel anticancer agent J. Med. Chem. 2011, 54, 2127-2142
19. Galkin, A. V.; Melnick, J. S.; Kim, S.; Hood, T. L.; Li, N.; Li, L.; Xia, G.; Steensma, R.; Chopiuk, G.; Jiang, J.; Wan, Y.; Ding, P.; Liu, Y.; Sun, F.; Schultz, P. G.; Gray, N. S.; Warmuth, M. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 270-275
20. Gingrich, D. E.; Lisko, J. G.; Curry, M. A.; Cheng, M.; Haltiwanger, R. C.; Wells-Knecht, K.; Ott, G. R.; Ghose, A. K.; Ator, M. A.; Ruggeri, B.; Dorsey, B. D. Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase J. Med. Chem. 2012, 55, 4580-4593
21. Mesaros, E. F.; Burke, J. P.; Parrish, J. D.; Dugan, B. J.; Anzalone, A. V.; Angeles, T. S.; Albom, M. S.; Ator, M. A.; Ruggeri, B. A.; Cheng, M.; Ott, G. R.; Dorsey, B. D. Bioorg. Med. Chem. Lett. 2011, 463-466
22. Zificsak, C. A.; Theroff, J. P.; Aimore, L. D.; Angeles, T. S.; Albom, M. S.; Underiner, T. L.; Wan, W.; Dorsey, B. D. Methanesulfonamido-cyclohexylamine derivatives of 2,4-diamino pyrimidine as potent ALK inhibitors Bioorg. Med. Chem. Lett. 2011, 21, 3877-3880
23. Zificsak, C. A.; Theroff, J. P.; Aimore, L. D.; Albom, M. S.; Angeles, T. S.; Worrell, C. S.; Zeigler, K. S.; Dorsey, B. D. 2,4-Diaminopyrimidine inhibitors of c-Met kinase bearing benzoxazepine anilines Bioorg. Med. Chem. Lett. 2011, 21, 660-663
24. Weinberg, L. R.; Albom, M. S.; Angeles, T. S.; Husten, J.; Lisko, J. G.; McHugh, R. J.; Ott, G. R.; Tripathy, R.; Underiner, T. L.; Zificsak, C. A.; Dorsey, B. D. Fused bicyclic derivatives of 2,4-diaminopyrimidine as c-Met inhibitors Bioorg. Med. Chem. Lett. 2011, 21, 164-167
25. Ott, G. R.; Tripathy, R.; Cheng, M.; McHugh, R.; Anzalone, A. V.; Ator, M. A.; Ruggeri, B. A.; Dorsey, B. D. Discovery of a potent inhibitor of anaplastic lymphoma kinase with in vivo antitumor activity ACS Med. Chem. Lett. 2010, 1, 493-499
26. Milkiewicz, K. L.; Aimone, L. D.; Albom, M. S.; Angeles, T. S.; Chang, H.; Grobelny, J. V.; Husten, J.; LoSardo, C.; Underiner, T. L.; Weinberg, L. R.; Worrell, C. S.; Zeigler, K. S.; Dorsey, B. D. Bioorg. Med. Chem. 2011, 19, 6274-6284
27. Ye, N.; Chen, C.-H.; Chen, T. T.; Song, Z.; He, J.; Huan, X.; Song, S.; Liu, Q.; Chen, Y.; Ding, J.; Xu, Y.; Miao, Z.; Zhang, A. Design, synthesis and biological evaluation of a series of benzo[de][1,7]naphthyridin-7(8 H)-ones bearing a functionalized longer chain appendage as novel PARP1 inhibitors J. Med. Chem. 2013, 56, 2885-2903
28. Zhang, J.; Xiong, B.; Zhen, X.; Zhang, A. Dopamine D1 receptor ligands: Where are we now and where are we going Med. Res. Rev. 2009, 29, 272-294
29. EI-Subbagh, H.; Wittig, T.; Decker, M.; Elz, S.; Nieger, M.; Lehmann, J. Arch. Pharm. Pharm. Med. Chem. 2002, 9, 443-448
30. Ye, N.; Neumeyer, J. L.; Baldessarini, R. J.; Zhen, X.; Zhang, A. Recent progress in the development of dopamine receptor subtype compounds: Potential therapeutic agents for neurological and neuropsychiatric disorders Chem. Rev. 2013, 113, PR123-PR178